Latest filings (excl ownership)
8-K
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United
11 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
7 Jun 24
ARS
2023 FY
Annual report to shareholders
9 May 24
DEF 14A
Definitive proxy
9 May 24
8-K
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
9 May 24
10-Q
2024 Q1
Quarterly report
8 May 24
PRE 14A
Preliminary proxy
29 Apr 24
424B3
Prospectus supplement
19 Apr 24
EFFECT
Notice of effectiveness
18 Apr 24
POS AM
Prospectus update (post-effective amendment)
12 Apr 24
8-K
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
1 Apr 24
424B3
Prospectus supplement
12 Mar 24
EFFECT
Notice of effectiveness
11 Mar 24
8-K
Regulation FD Disclosure
4 Mar 24
POS AM
Prospectus update (post-effective amendment)
28 Feb 24
8-K
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
15 Feb 24
424B5
Prospectus supplement for primary offering
15 Feb 24
424B5
Prospectus supplement for primary offering
13 Feb 24
8-K
Regulation FD Disclosure
22 Jan 24
8-K
NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors
8 Jan 24
8-K
NewAmsterdam Pharma Announces 2024 Strategic Priorities
4 Jan 24
EFFECT
Notice of effectiveness
20 Dec 23
424B3
Prospectus supplement
19 Dec 23
F-3
Shelf registration (foreign)
7 Dec 23
424B3
Prospectus supplement
13 Nov 23
6-K
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
13 Nov 23
6-K
NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer
23 Oct 23
6-K
Current report (foreign)
25 Sep 23
424B3
Prospectus supplement
21 Sep 23
6-K
NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients
21 Sep 23
6-K
Current report (foreign)
28 Aug 23
424B3
Prospectus supplement
15 Aug 23
6-K
NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer
14 Aug 23
EFFECT
Notice of effectiveness
14 Aug 23
POS AM
Prospectus update (post-effective amendment)
7 Aug 23
6-K
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights
7 Aug 23
6-K
Research and development expenses
7 Aug 23
6-K
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating
26 Jul 23
Latest ownership filings
3
WILLIAM A JONES JR
3 May 24
4
Juliette Berangere Audet
2 Apr 24
4
James N Topper
28 Mar 24
4
Johannes Jacob Pieter Kastelein
27 Mar 24
144
Notice of proposed sale of securities
26 Mar 24
SC 13D/A
BCLS II Investco, LP
1 Mar 24
4
LOUIS G LANGE
21 Feb 24
SC 13D/A
Frazier Life Sciences X, L.P.
21 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
VIKING GLOBAL INVESTORS LP
14 Feb 24
3/A
Michael H. Davidson
25 Jan 24
3/A
LOUIS G LANGE
25 Jan 24
4
William Lewis
8 Jan 24
3
William Lewis
8 Jan 24
4
Louise Frederika Kooij
3 Jan 24
4
Douglas F Kling
3 Jan 24
4
der Kamp Hilde Johanna van
3 Jan 24
4
LOUIS G LANGE
3 Jan 24
4
Johannes Jacob Pieter Kastelein
3 Jan 24
4
Michael H. Davidson
3 Jan 24
4
John W Smither
3 Jan 24
4
Mayur Ian Somaiya
3 Jan 24
3
Initial statement of insider ownership
2 Jan 24
3
Initial statement of insider ownership
29 Dec 23
3
Nicholas Downing
29 Dec 23
3
Juliette Berangere Audet
29 Dec 23
3
John W Smither
29 Dec 23
3
James N Topper
29 Dec 23
3
Johannes Jacob Pieter Kastelein
29 Dec 23
3
Douglas F Kling
29 Dec 23
3
Michael H. Davidson
29 Dec 23
3
Hugo Alexander Slootweg
29 Dec 23
3
Louise Frederika Kooij
29 Dec 23
3
LOUIS G LANGE
29 Dec 23
3
Mayur Ian Somaiya
29 Dec 23
3
der Kamp Hilde Johanna van
29 Dec 23
SC 13G/A
Morningside Venture Investments Ltd
19 Sep 23
SC 13D/A
Frazier Life Sciences X, L.P.
15 Aug 23
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
1 Aug 23
SC 13D/A
Forbion Capital Fund IV Cooperatief U.A.
7 Jul 23